These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 38394523)
1. Association with the plasma atherogenic index with hepatic steatosis and fibrosis in the US population. Li Y; Men X; Liu Y; Jiang H; Bi C; Qu Y; Wang K; Wang X; Jing J; Liu Y Medicine (Baltimore); 2024 Feb; 103(8):e37152. PubMed ID: 38394523 [TBL] [Abstract][Full Text] [Related]
2. Association between weight-adjusted-waist index with hepatic steatosis and liver fibrosis: a nationally representative cross-sectional study from NHANES 2017 to 2020. Shen Y; Wu Y; Fu M; Zhu K; Wang J Front Endocrinol (Lausanne); 2023; 14():1159055. PubMed ID: 37274346 [TBL] [Abstract][Full Text] [Related]
3. Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS. Xie R; Zhang Y Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1179-1189. PubMed ID: 36964061 [TBL] [Abstract][Full Text] [Related]
4. Association between SII and hepatic steatosis and liver fibrosis: A population-based study. Xie R; Xiao M; Li L; Ma N; Liu M; Huang X; Liu Q; Zhang Y Front Immunol; 2022; 13():925690. PubMed ID: 36189280 [TBL] [Abstract][Full Text] [Related]
5. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863 [TBL] [Abstract][Full Text] [Related]
6. The association between atherogenic index of plasma and metabolic dysfunction-associated fatty liver disease as detected by FibroScan. Wang A; Li J; Li L; Ding H; Yang N; Xu M Nutr Hosp; 2024 Apr; 41(2):384-392. PubMed ID: 38328923 [TBL] [Abstract][Full Text] [Related]
7. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971 [TBL] [Abstract][Full Text] [Related]
8. Inverted U-shaped relationships between bone mineral density and VCTE-quantified degree of hepatic steatosis in adolescents: Evidence from the NHANES. He S; Zhang Y; Tan C; Tan W; Yin B PLoS One; 2023; 18(6):e0286688. PubMed ID: 37294745 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the mediating role of BMI in associations of different folate forms with hepatic steatosis and liver fibrosis in adolescents in the USA: results from the NHANES 2017-2018. Wen J; Fei Y; Yuan L; Li K; Xu Q; Cao X; Su J; Zhu Y; Zhang Z Front Endocrinol (Lausanne); 2023; 14():1273580. PubMed ID: 38116318 [TBL] [Abstract][Full Text] [Related]
11. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. Lee JI; Lee HW; Lee KS World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686 [TBL] [Abstract][Full Text] [Related]
12. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016 [TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease. Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946 [TBL] [Abstract][Full Text] [Related]
14. Association of serum uric acid with hepatic steatosis detected by controlled attenuation parameter in the United States population. Feng Y; Zheng S; Liu L; Yang Y Lipids Health Dis; 2023 Jun; 22(1):76. PubMed ID: 37340407 [TBL] [Abstract][Full Text] [Related]
15. Serum vitamin D is associated with ultrasound-defined hepatic fibrosis. Jiang R; Zhou Y; Han L; Hong Z Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102228. PubMed ID: 37865224 [TBL] [Abstract][Full Text] [Related]
16. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761 [TBL] [Abstract][Full Text] [Related]
17. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622 [TBL] [Abstract][Full Text] [Related]
18. Correlation between ZJU index and hepatic steatosis and liver fibrosis in American adults with NAFLD. Luo S; Weng X; Xu J; Lin H Front Med (Lausanne); 2024; 11():1443811. PubMed ID: 39211343 [TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617 [TBL] [Abstract][Full Text] [Related]
20. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]